FAM73A Inhibitors
FAM73A inhibitors encompass a diverse array of chemical compounds tha attenuate the functional activity of FAM73A through modulation of specific signaling pathways to which FAM73A is linked. LY 294002 and Wortmannin, as potent PI3K inhibitors, diminish downstream PI3K signaling, effectively reducing FAM73A activity that is contingent on PI3K's role in cellular communication. The mTOR pathway, a critical component of the PI3K axis, can also be targeted by compounds like Rapamycin, which suppresses mTOR signaling, thereby indirectly attenuating FAM73A's functional role. Similarly, MAPK pathway inhibitors such as PD 98059, SB 203580, SP600125, and U0126, which target different kinases like MEK1/2, p38 MAPK, and JNK, impede respective kinase-mediated signaling processes, leading to reduced FAM73A-related functions. Inhibition of these kinases interrupts the phosphorylation cascade that could otherwise enhance FAM73A's activity. Conversely, inhibitors such as Dasatinib and PP 2, which target the Src family of tyrosine kinases, indirectly curtail FAM73A activity by impeding upstream kinase signaling that may regulate FAM73A's involvement in cellular processes.
Focusing on alterations in cytoskeletal dynamics and related signaling, Y-27632, a ROCK inhibitor, disrupts actin cytoskeleton organization and, consequently, any FAM73A-associated functions that rely on the structural integrity and signaling related to the cytoskeleton. Further, Gö 6983 inhibits protein kinase C (PKC), which can affect a myriad of cellular processes including those in which FAM73A may have a role, leading to a decrease in FAM73A's activity through the cessation of PKC-mediated modulation. Lastly, BIX 02189 specifically inhibits MEK5, a kinase within the MAPK pathway, thereby diminishing ERK5-dependent signaling, which may encompass FAM73A's functional repertoire. Collectively, these inhibitors function through distinct but interrelated pathways, ultimately converging on the diminution of FAM73A's functional activity without affecting its expression levels.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A specific inhibitor of phosphatidylinositol 3-kinase (PI3K). Since FAM73A is involved in cellular processes that are PI3K-dependent, inhibition of PI3K by LY294002 would lead to a decrease in FAM73A-related signaling, thereby diminishing its functional activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can suppress the mTOR pathway, which is an important downstream component of PI3K signaling. This suppression would indirectly diminish the functional activity of FAM73A, as it is associated with the PI3K pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A selective inhibitor of MEK1/2 within the MAPK/ERK pathway. By inhibiting MEK1/2, PD 98059 indirectly decreases ERK-mediated signaling processes that could include FAM73A's functions, thus diminishing its activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that would diminish the p38-mediated signaling pathways. Since FAM73A may function within cellular processes regulated by the p38 MAPK, SB 203580 would indirectly decrease FAM73A's activity via inhibition of this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), part of the MAPK pathway. By inhibiting JNK, SP600125 can decrease signaling processes that are potentially connected to FAM73A function, thus leading to reduced FAM73A activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A PI3K inhibitor that acts by irreversibly inhibiting the enzyme, leading to diminished downstream signaling including pathways in which FAM73A may be involved, thereby decreasing its functional activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A selective inhibitor of MEK1/2, similar to PD98059, that leads to a decrease in ERK phosphorylation and activity. Given FAM73A's potential role in MEK/ERK-dependent processes, U0126 would indirectly lead to diminished FAM73A activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
A tyrosine kinase inhibitor that can inhibit Src family kinases. Since Src kinases can be upstream of signaling pathways involving FAM73A, dasatinib would indirectly lead to a decrease in FAM73A activity by inhibiting these kinases. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
An Src family kinase inhibitor. By inhibiting Src kinases, PP 2 would lead to diminished Src-dependent signaling pathways, which could include those in which FAM73A is involved, thus indirectly decreasing FAM73A functional activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A selective inhibitor of ROCK (Rho-associated protein kinase), which can affect actin cytoskeleton dynamics. Since FAM73A may be involved in cellular processes dependent on the cytoskeleton, inhibition by Y-27632 could lead to diminished FAM73A activity. | ||||||